Connecting clinical care, data and research
PartnershipsContact
← Back to publications

RESEARCH PUBLICATION / 2024

Original Article

Association of Paxlovid use with cardiovascular risk after COVID-19 infection in patients with autoimmune rheumatic diseases

Paxlovid use is associated with lower risk of cardiovascular diseases in COVID-19 patients with autoimmune rheumatic diseases: a retrospective cohort study.

BMC Medicine

Citation & Authors

BMC Med. 2024;22(1):117.

Weijie Wang; Yu-Hsun Wang; Ching-Hua Huang; Tsung-Hsueh Hsieh; Gema Hernández Ibarburu; James Cheng-Chung Wei

ABSTRACT · CHINESE TRANSLATION

Translated abstract

Translated from the licensed abstract via the Chinese version. This is not an official journal translation.

background

Paxlovid has been shown to reduce mortality and hospitalization in patients with COVID-19. However, whether it reduces cardiovascular disease risk in patients with autoimmune rheumatic diseases (AIRDs) who survive the infection remains unclear.

method

Using TriNetX US Collaborative Network data, this study identified 5,671,395 patients with AIRDs between January 1, 2010, and December 31, 2021. The cohort included 238,142 of these patients diagnosed with COVID-19 between January 1 and December 31, 2022. Patients were grouped by Paxlovid use, and propensity score matching balanced baseline characteristics. HRs and 95% confidence intervals were compared for cardiovascular outcomes, hospitalization, death, and intensive care unit (ICU) admission. Subgroup analyses considered sex, age, race, and autoimmune disease category. Sensitivity analyses examined treatment started on the first day of COVID-19 diagnosis or on days 2–5.

result

Paxlovid use was associated with lower risks of cerebrovascular complications (HR 0.65; 95% CI 0.47–0.88), arrhythmias (0.81; 0.68–0.94), and ischemic heart disease and other cardiac diseases (0.51; 0.35–0.74), including heart failure (0.41; 0.26–0.63). Among thrombotic disorders, deep vein thrombosis was also less frequent (0.46; 0.24–0.87). Compared with nonusers, the Paxlovid group had lower risks of major adverse cardiac events (0.56; 0.44–0.70) and any of the cardiovascular outcomes above (0.76; 0.66–0.86), as well as significantly lower risks of death (0.21; 0.11–0.40), hospitalization (0.68; 0.60–0.76), and ICU admission (0.52; 0.33–0.80). The associations appeared more pronounced in men, older patients, and Black patients with AIRDs. Prescription of Paxlovid on the first day of COVID-19 diagnosis was associated with significant reductions in cardiovascular outcomes and severe disease.

Conclusion

Among patients with AIRDs who survived COVID-19, Paxlovid use was associated with lower risks of cardiovascular disease and severe illness.

Original work: Author of the above paper. Source:Public Summary ↗. This translation is based on the Chinese rendering of the original English abstract.

Original work license:CC BY ↗;Translations are subject to the same licensing conditions.